Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.

Publication ,  Journal Article
Speca, J; Yenser, S; Creel, P; George, D
Published in: Clin Genitourin Cancer
December 2006

With the approval of sunitinib and sorafenib, 2 new multitargeted tyrosine kinase inhibitors, for the treatment of advanced renal cell carcinoma (RCC), the natural history and prognosis of patients with this disease has significantly improved. These drugs were approved based upon clinical data demonstrating robust, unprecedented response rates in one case and dramatic prolongation of progression-free survival in the other. In both cases, these results were seen in study patients in whom standard therapy had failed and who, on average, carried substantial disease burden. Important challenges today include integrating these therapies with other standard therapeutic options and into other advanced-stage RCC patient populations. This article addresses current data and practice patterns regarding the clinical use of tyrosine kinase inhibitors in patients with advanced-stage RCC, including dose modifications and alternative dosing, the current role of debulking nephrectomy, and use in patients with indolent disease. Finally, a summary of the more common side effects and management strategies for these is also discussed. Ultimately, more clinical data is needed to address the chronic use of these agents alone, in combination with other agents, with radiation therapy, and in sequence.

Duke Scholars

Published In

Clin Genitourin Cancer

DOI

ISSN

1558-7673

Publication Date

December 2006

Volume

5 Suppl 1

Start / End Page

S24 / S30

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sunitinib
  • Sorafenib
  • Pyrroles
  • Pyridines
  • Protein Kinase Inhibitors
  • Phenylurea Compounds
  • Oncology & Carcinogenesis
  • Niacinamide
  • Nephrectomy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Speca, J., Yenser, S., Creel, P., & George, D. (2006). Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer, 5 Suppl 1, S24–S30. https://doi.org/10.3816/cgc.2006.s.004
Speca, JoEllen, Sarah Yenser, Patricia Creel, and Daniel George. “Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.Clin Genitourin Cancer 5 Suppl 1 (December 2006): S24–30. https://doi.org/10.3816/cgc.2006.s.004.
Speca J, Yenser S, Creel P, George D. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S24–30.
Speca, JoEllen, et al. “Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.Clin Genitourin Cancer, vol. 5 Suppl 1, Dec. 2006, pp. S24–30. Pubmed, doi:10.3816/cgc.2006.s.004.
Speca J, Yenser S, Creel P, George D. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S24–S30.
Journal cover image

Published In

Clin Genitourin Cancer

DOI

ISSN

1558-7673

Publication Date

December 2006

Volume

5 Suppl 1

Start / End Page

S24 / S30

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sunitinib
  • Sorafenib
  • Pyrroles
  • Pyridines
  • Protein Kinase Inhibitors
  • Phenylurea Compounds
  • Oncology & Carcinogenesis
  • Niacinamide
  • Nephrectomy